| How can attrition rates be reduced in cancer drug discovery? L Moreno, ADJ Pearson Expert opinion on drug discovery 8 (4), 363-368, 2013 | 139 | 2013 |
| Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence L Moreno, F Bautista, S Ashley, C Duncan, S Zacharoulis European Journal of Cancer 46 (12), 2253-2259, 2010 | 111 | 2010 |
| Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis S Zacharoulis, S Ashley, L Moreno, JC Gentet, M Massimino, D Frappaz Child's nervous system 26, 905-911, 2010 | 111 | 2010 |
| Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer G Vassal, R Rousseau, P Blanc, L Moreno, G Bode, S Schwoch, ... European journal of cancer 51 (2), 218-224, 2015 | 101 | 2015 |
| Ependymoma: an update S Zacharoulis, L Moreno Journal of child neurology 24 (11), 1431-1438, 2009 | 91 | 2009 |
| Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature D Schrey, F Carceller Lechón, G Malietzis, L Moreno, C Dufour, S Chi, ... Journal of neuro-oncology 126, 81-90, 2016 | 89 | 2016 |
| Factors associated with recurrence and survival length following relapse in patients with neuroblastoma NO Basta, GC Halliday, G Makin, J Birch, R Feltbower, N Bown, M Elliott, ... British journal of cancer 115 (9), 1048-1057, 2016 | 88 | 2016 |
| First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors D Ruano, JA López-Martín, L Moreno, Á Lassaletta, F Bautista, M Andión, ... Molecular Therapy 28 (4), 1033-1042, 2020 | 81 | 2020 |
| Outcome of children with relapsed or refractory neuroblastoma: a meta‐analysis of ITCC/SIOPEN European phase II clinical trials L Moreno, H Rubie, A Varo, MC Le Deley, L Amoroso, A Chevance, ... Pediatric Blood & Cancer 64 (1), 25-31, 2017 | 75 | 2017 |
| Risk stratification of high‐risk metastatic neuroblastoma: a report from the HR‐NBL‐1/SIOPEN study DA Morgenstern, U Pötschger, L Moreno, V Papadakis, C Owens, S Ash, ... Pediatric blood & cancer 65 (11), e27363, 2018 | 69 | 2018 |
| Early phase clinical trials of anticancer agents in children and adolescents—an ITCC perspective L Moreno, ADJ Pearson, X Paoletti, I Jimenez, B Geoerger, PR Kearns, ... Nature Reviews Clinical Oncology 14 (8), 497-507, 2017 | 65 | 2017 |
| Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development strategy forum from innovative therapies for children with cancer and … L Moreno, G Barone, SG DuBois, J Molenaar, M Fischer, J Schulte, ... European Journal of Cancer 136, 52-68, 2020 | 61 | 2020 |
| The challenge of defining “ultra‐high‐risk” neuroblastoma DA Morgenstern, R Bagatell, SL Cohn, MD Hogarty, JM Maris, L Moreno, ... Pediatric Blood & Cancer 66 (4), e27556, 2019 | 59 | 2019 |
| Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update F Bautista, V Fioravantti, T de Rojas, F Carceller, L Madero, A Lassaletta, ... Cancer medicine 6 (11), 2606-2624, 2017 | 58 | 2017 |
| Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study M Fischer, L Moreno, DS Ziegler, LV Marshall, CM Zwaan, MS Irwin, ... The Lancet Oncology 22 (12), 1764-1776, 2021 | 57 | 2021 |
| A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations SL George, E Izquierdo, J Campbell, E Koutroumanidou, P Proszek, ... European Journal of Cancer 121, 224-235, 2019 | 56 | 2019 |
| MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance G Barone, D A Tweddle, J M Shohet, L Chesler, L Moreno, A DJ Pearson, ... Current drug targets 15 (1), 114-123, 2014 | 55 | 2014 |
| A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study L Moreno, LV Marshall, ADJ Pearson, B Morland, M Elliott, ... Clinical Cancer Research 21 (2), 267-273, 2015 | 51 | 2015 |
| A simple vibrating sample magnetometer for macroscopic samples V Lopez-Dominguez, A Quesada, JC Guzmán-Mínguez, L Moreno, ... Review of Scientific Instruments 89 (3), 2018 | 49 | 2018 |
| Accelerating drug development for neuroblastoma-new drug development strategy: an innovative therapies for children with cancer, European network for cancer research in … L Moreno, H Caron, B Geoerger, A Eggert, G Schleiermacher, P Brock, ... Expert opinion on drug discovery 12 (8), 801-811, 2017 | 49 | 2017 |
Stergios ZacharoulisColumbia University Medical Center在 cumc.columbia.edu 的电子邮件经过验证
